Biomoda is a cancer diagnostics company focused on the development of an inexpensive, simple, highly accurate in-vitro test for the early detection of lung cancer. The CyPath®  assay is based upon Biomoda’s patent estate centered on molecular marker technology originally developed at the Los Alamos National Laboratory.  

Biomoda trades under the symbol BMOD (OTC Bulletin Board) and files regular reports with the U.S. Securities and Exchange Commission (SEC), available on the SEC’s EDGAR site.  Administrative offices and current research and development operations and laboratory functions, including a microscopy lab, assay development and formulation lab, are located at 609 Broadway NE in Albuquerque, New Mexico.  

In recent years, lung cancer has become the leading cause of cancer deaths worldwide with 1.2 million new cases reported annually.  More than 170,000 Americans are diagnosed with the disease each year, and typically diagnosis is not made until the disease has advanced to Stage III or IV, resulting in a dismal five-year survival rate of only 15%.  Early detection increases the survival rate to approximately 92%, according to an I-ELCAP study published in the New England Journal of Medicine.  

Biomoda is seeking U.S. Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device under the Pre-Market Approval (PMA) process.  

Future product and market extensions will focus on the diagnosis, screening and monitoring of other cancers. Assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development, as well as circulating tumor cell (CTC) technologies.  The commercial viability of an inexpensive, highly accurate diagnostic test is a strong market-driven opportunity.   

We believe the Biomoda technology represents a significant market opportunity by addressing a global health crisis.  Pending FDA approval of the initial assay for detection of early-stage lung cancer, Biomoda expects its products will find rapid and broad acceptance in the marketplace by offering high sensitivity and accuracy at the cellular level, simple noninvasive use and very affordable cost.